Thymalin: What It Is, Research & Safety (2026)

Thymalin is a polypeptide complex extracted from thymus tissue, developed in Russia as an immunomodulatory drug and one of the original Khavinson "bioregulators". It is not the same as thymosin alpha-1. Thymalin is a mixture of peptides, while thymosin alpha-1 is a single defined 28-amino-acid peptide. Thymalin's human evidence consists of older Russian clinical studies and non-randomized COVID-19 reports, nearly all from its developers' network. It is not FDA-approved and is not on the 503A Bulks List.

Educational content for licensed healthcare professionals. Not medical advice; dosing and treatment decisions belong to the prescribing clinician.

Thymalin vs Thymosin Alpha-1

The two names are often confused, and the differences matter for evidence and for regulation.

In short, thymosin alpha-1 is a defined drug molecule with a broad international trial record [6]. Thymalin is a tissue extract with a narrower and less independent evidence base. Data for one cannot be used for the other.

What Is Thymalin?

Thymalin was among the first products of Vladimir Khavinson's bioregulator program. A 2020 paper from the group describes it as "a polypeptide complex isolated from the thymus and regulating the functions of the immune system" [1]. It has been used in Russia in respiratory and immune conditions. Later work identified two dipeptides as active components: KE (Lys-Glu), also sold separately as the synthetic bioregulator Vilon, and EW (Glu-Trp) [3].

For background on the whole family, including Testagen and Epitalon, see our Testagen vs TRT comparison, which explains how bioregulators are claimed to work.

What the Research Shows

Laboratory: stem-cell differentiation and cytokines

In cultures of human hematopoietic stem cells, Thymalin reduced the stem-cell markers CD44 and CD117 and increased CD28, a T-cell co-stimulatory molecule. The authors interpreted this as Thymalin pushing progenitor cells toward mature T lymphocytes [1].

A 2023 study combined molecular docking and bioinformatics, used to predict which genes the KE and EW dipeptides might bind, with a lab model of inflammation in human blood mononuclear cells. It reported effects on the inflammatory cytokines IL-1β, IL-6 and TNFα. Blood came from four donors [3].

Evidence level: in vitro and computational.

Long-term observational data in older adults

The most often cited human study is a 2003 report on older adults given Thymalin, Epithalamin (a pineal extract), or both during the first 2–3 years of 6–8 years of observation. The authors reported fewer acute respiratory illnesses and mortality 2.0–2.1-fold lower in the Thymalin group than in controls [4].

Interpret this cautiously. The abstract does not describe randomization or blinding, and the result has not been independently replicated. An effect this large on all-cause mortality would need confirmation in a modern controlled trial.

Evidence level: human, observational or controlled design not fully described; single group.

COVID-19 reports

During the pandemic, the developers and collaborators reported adding Thymalin to standard care in hospitalized patients with COVID-19:

• One report found that adding Thymalin sped up the decline in IL-6, C-reactive protein and D-dimer and improved T-cell indicators compared with standard treatment [2].
• A Russian-language comparison of severe COVID-19 patients found hospital mortality of 40.9% with standard therapy, 28.4% with tocilizumab, and 20.6% with Thymalin, alongside changes in lymphocyte counts and clotting markers [5].

These were not described as randomized, blinded trials. Mortality differences between non-randomized groups can reflect who received which treatment rather than any effect of the drug.

Evidence level: small, non-randomized clinical reports.

How Strong Is the Thymalin Evidence?

• Mostly one research network. The studies above come from Khavinson's institute and its collaborators.
• Language barrier. Several primary reports are Russian-language, with only abstracts in PubMed.
• Variable composition. As an extract, Thymalin's composition may vary between batches and manufacturers. Products sold online under the name may not match the product studied.
• No modern randomized trials of Thymalin were found in the indexed literature.

Safety Considerations

Published Thymalin studies do not provide a systematic adverse-event profile. Considerations for prescribers:

• Biologic-extract risks. Animal-derived peptide mixtures carry potential for immune or hypersensitivity reactions and batch-to-batch variability.
• Immune modulation. Thymalin is intended to change immune function. Use alongside immunosuppressive therapy, in autoimmune disease, or after organ transplant has not been studied.
• Malignancy. Agents proposed to stimulate cell differentiation and immune activity have not been evaluated in patients with active cancer.
• Quality. Research-chemical and imported products carry no U.S. assurance of identity, purity, sterility or endotoxin limits.
• Special populations. No data in pregnancy, breastfeeding, or children in the indexed literature.

Regulatory Status (October 2026)

Thymalin is not FDA-approved and is not on the 503A Bulks List. It was not among the substances considered at FDA's July 23–24, 2026 Pharmacy Compounding Advisory Committee meeting. Because it is a tissue extract rather than a defined bulk drug substance, it also does not fit the 503A bulk-substance framework the way a single synthetic peptide does.

Thymosin alpha-1 is regulated separately. It is not FDA-approved in the U.S. but is approved internationally as Zadaxin. Check the FDA Peptide Status Tracker for current status of both.

Newtropin does not prescribe, compound, or dispense. We connect licensed providers with licensed 503A partner pharmacies covering all 50 states and D.C.; prescribers can start at For Providers.

Frequently Asked Questions

What is Thymalin?

Thymalin is a polypeptide complex extracted from thymus tissue, developed in Russia as an immunomodulatory drug. It is one of the original Khavinson bioregulators. Its reported active components include the dipeptides Lys-Glu and Glu-Trp.

Is Thymalin the same as thymosin alpha-1?

No. Thymalin is a mixture of peptides extracted from thymus tissue. Thymosin alpha-1 (thymalfasin) is a single defined 28-amino-acid peptide with an international clinical trial record and approval in a number of countries as Zadaxin. Their evidence and regulatory status are separate.

Did Thymalin help COVID-19 patients?

Russian reports described faster improvement in inflammatory markers and lower hospital mortality when Thymalin was added to standard care. These studies were not described as randomized or blinded, so they cannot establish that Thymalin caused the differences.

Is Thymalin safe?

Systematic human safety data are not available in the indexed literature. As an animal-tissue extract it carries potential for hypersensitivity and batch variability, and its use with immunosuppressants or in autoimmune disease has not been studied.

Can U.S. pharmacies compound Thymalin?

Thymalin is not FDA-approved and is not on the 503A Bulks List, and it was not reviewed at the July 2026 PCAC meeting. Check the FDA Peptide Status Tracker for any change.

References

1. Khavinson VK, et al. Thymalin: Activation of Differentiation of Human Hematopoietic Stem Cells. Bull Exp Biol Med. 2020;170(1):118-122. PubMed
2. Khavinson VK, et al. Results and Prospects of Using Activator of Hematopoietic Stem Cell Differentiation in Complex Therapy for Patients with COVID-19. Stem Cell Rev Rep. 2021;17(1):285-290. PubMed
3. Linkova N, et al. The Influence of KE and EW Dipeptides in the Composition of the Thymalin Drug on Gene Expression and Protein Synthesis Involved in the Pathogenesis of COVID-19. Int J Mol Sci. 2023;24(17):13377. PubMed
4. Khavinson VKh, Morozov VG. Peptides of pineal gland and thymus prolong human life. Neuro Endocrinol Lett. 2003;24(3-4):233-240. PubMed
5. Kuznik BI, et al. Morphological compound and indicators of the blood clotting system in severe COVID-19 patients of middle aged and elderly during treatment of Tocilizumab and Thymalin [in Russian]. Adv Gerontol. 2022;35(3):368-374. PubMed
6. Dominari A, et al. Thymosin alpha 1: A comprehensive review of the literature. World J Virol. 2020;9(5):67-78. PubMed
7. Khavinson VK, et al. Peptide Regulation of Gene Expression: A Systematic Review. Molecules. 2021;26(22):7053. PubMed